Steve Jobs and a Rare Kind of Pancreatic Cancer

What Steve Jobs told Apple employees

In August 2004, Steve Jobs, then 49, emailed Apple staff about his health. ABC News later published the text.

"I had a very rare form of pancreatic cancer called an islet cell neuroendocrine tumor," he wrote. He said it "represents about 1 percent of the total cases of pancreatic cancer diagnosed each year, and can be cured by surgical removal if diagnosed in time (mine was)." He added: "I will not require any chemotherapy or radiation treatments."

Jobs died on October 5, 2011. Much of his medical course stayed private, and this article does not fill the gaps. His email did teach many people one thing that matters. Pancreatic cancer is not one disease. The phrase covers two conditions with very different outlooks.

The pancreas is really two organs

Scientific American put it plainly when reporting on Jobs's illness. The pancreas is really two organs bundled together.

Most of its bulk is exocrine tissue. That part makes digestive enzymes and sends them to the gut through ducts. Cancers here are adenocarcinomas, and they are the vast majority of pancreatic cancer.

Scattered inside that bulk are thousands of tiny islands of endocrine tissue, called islets. These make hormones and release them into the blood. Cancers here are pancreatic neuroendocrine tumors, or islet cell tumors. That is what Jobs described.

Islet cell tumors, in NCI's terms

The National Cancer Institute calls pancreatic neuroendocrine tumors uncommon, with about 1,000 new cases a year in the United States. They account for less than 2% of pancreatic malignancies, and overall they carry a better prognosis than the far more common exocrine tumors.

NCI divides them by whether they make hormones. Functional tumors produce one or more active hormones. They usually announce themselves through the effects of those hormones, not through the size of the tumor. NCI lists gastrinoma, insulinoma, glucagonoma, somatostatinoma, and VIPoma.

About 15% are nonfunctional. They make no hormone syndrome, so NCI notes they tend to appear at later stages, with symptoms from the mass itself or from spread.

Most are sporadic, meaning they arise with no inherited cause. Some are part of an inherited syndrome called multiple endocrine neoplasia type 1.

The much more common kind

Exocrine pancreatic adenocarcinoma is what most people mean by "pancreatic cancer."

The 67,530 new pancreatic cancer cases and 52,740 deaths projected for the United States in 2026 are American Cancer Society estimates, and NCI's PDQ summary carries the Society's count as its reference 1. It ranks fourth among causes of cancer death in men and third in women. Despite that toll, NCI adds, the causes of the disease are poorly understood.

NCI lists these risk factors. A family history of pancreatic cancer. Cigarette smoking. Obesity. Chronic pancreatitis. And certain genetic conditions, including those linked to the BRCA1, BRCA2, PALB2, and ATM genes.

When to get checked

NCI states that in the early stages there are not many noticeable symptoms. As the cancer grows, it lists:

• Jaundice, meaning yellowing of the skin or eyes.
• Light-colored stools or dark urine.
• Pain in the upper or middle abdomen and in the back.
• Weight loss for no known reason.
• Loss of appetite.
• Fatigue.

Practical thresholds:

• Painless jaundice in an adult is not a wait-and-see symptom. Yellow eyes or skin, pale stools, or dark urine with no fever needs care that week.
• Upper abdominal pain that bores through to the back, is worse lying flat, and eases leaning forward, for more than two weeks.
• Unintended weight loss with appetite loss, especially over one to two months.
• Two or more close relatives with pancreatic cancer, or a known BRCA gene change in the family, is a reason to ask about genetic counseling.

There is no screening program for pancreatic cancer at average risk.

Why it is so hard to find early

NCI gives three reasons. There are no noticeable signs in the early stages. When signs do appear, they look like those of many other illnesses, including pancreatitis and ulcers. And the pancreas sits behind other organs, so it is hard to see clearly on imaging.

Blood tests do not rescue the situation. NCI states that no tumor-specific markers exist for pancreatic cancer. CA 19-9 has low specificity, and a normal level does not rule out recurrence.

Imaging includes helical CT, MRI, and endoscopic ultrasonography. In that last test an ultrasound probe on an endoscope gets close to the pancreas from inside the gut.

One detail in the biology gives room for hope. Scientific American reported research finding that pancreatic cancer takes about seven years on average to build a substantial tumor. It takes closer to a decade before it starts moving to other organs. That long silent window is what a future early-detection test would aim at.

What treatment involves

NCI states that surgery is the mainstay of curative treatment. It gives a survival benefit in small, localized tumors. But NCI says it should be considered only alongside systemic drug therapy. People with unresectable, metastatic, or recurrent disease are unlikely to benefit from surgery.

NCI recommends care by a multidisciplinary team. It also notes that patients at any stage are candidates for clinical trials, because standard chemotherapy, radiation, and surgery work poorly.

Palliative care matters here more than in most cancers. NCI lists drainage of a blocked bile duct, relief of stomach outlet obstruction, pain control, and psychological care.

The numbers, and what they hide

These figures describe groups. They do not describe a person, and they average across two diseases with different behavior.

SEER, the federal cancer statistics program, lists 67,530 new pancreatic cancers in the United States for 2026 and 52,740 deaths, and labels both as American Cancer Society projections. That is about 3.2% of new cancer diagnoses and 8.4% of cancer deaths. Five-year relative survival across all stages is 13.7% for people diagnosed from 2016 to 2022.

Stage explains that number. SEER records five-year relative survival of 43.6% for localized disease, 17.0% for regional disease, and 3.4% for distant disease. Only about 15% are found localized. Roughly 51% are already distant.

NCI's figures for exocrine pancreatic cancer are equally stark. It is rarely curable, with an overall survival rate below 6%. Truly localized disease is less than 20% of cases. For small localized tumors under 2 cm, with no lymph node spread and no growth beyond the capsule, complete surgery is linked to a five-year survival rate of 18% to 24%.

Set that against NCI's statement that neuroendocrine tumors carry a better prognosis overall. That is why Jobs's email mattered. When someone says "pancreatic cancer," the first useful question is which of the two organs it started in.

Sources

• NCI: Pancreatic Cancer Treatment (PDQ) — Health Professional Version
• NCI: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ) — Health Professional Version
• SEER Cancer Stat Facts: Pancreatic Cancer
• American Cancer Society: Cancer Facts & Statistics
• ABC News: Steve Jobs' Pancreatic Cancer — A Timeline
• Scientific American: The Puzzle of Pancreatic Cancer — How Steve Jobs Did Not Beat the Odds